UniProt Q8TDC3 · PDB · AlphaFold · Substrate: CHKtide · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Repotrectinib | 89.7% | 10.3% | 84.21 | 0.608 |
| 2 | Axitinib | 81.7% | 18.3% | 93.23 | 0.688 |
| 3 | Midostaurin | 81.4% | 18.6% | 78.64 | 0.500 |
| 4 | Brigatinib | 62.7% | 37.3% | 82.96 | 0.513 |
| 5 | Sunitinib | 43.2% | 56.8% | 91.73 | 0.524 |
| 6 | Dabrafenib | 32.2% | 67.8% | 94.74 | 0.633 |
| 7 | Defactinib | 28.2% | 71.8% | 92.68 | 0.450 |
| 8 | Rabusertib | 22.0% | 78.0% | 98.74 | 0.687 |
| 9 | Lorlatinib | 21.0% | 79.0% | 97.24 | 0.694 |
| 10 | Selpercatinib | 20.3% | 79.7% | 96.72 | 0.635 |
| 11 | Crizotinib | 14.6% | 85.4% | 91.39 | 0.581 |
| 12 | Canertinib | 13.0% | 87.0% | 96.49 | 0.671 |
| 13 | Gilteritinib | 12.4% | 87.6% | 88.97 | 0.506 |
| 14 | Nintedanib | 12.2% | 87.8% | 90.23 | 0.608 |
| 15 | Baricitinib | 10.4% | 89.6% | 97.99 | 0.616 |
| 16 | Larotrectinib | 10.3% | 89.7% | 99.25 | 0.710 |
| 17 | Abrocitinib | 10.2% | 89.8% | 99.50 | 0.581 |
| 18 | Dacomitinib | 9.7% | 90.3% | 97.99 | 0.664 |
| 19 | Avapritinib | 8.7% | 91.3% | 97.73 | 0.644 |
| 20 | Gefitinib | 8.3% | 91.7% | 99.25 | 0.650 |
Paralog block
BRSK1, BRSK2
EMT expression
- Mesenchymal log2(TPM+1): 2.52
- Epithelial log2(TPM+1): 1.92
- Fold change: 0.60
- Status: No significant change
Selectivity landscape vs inhibition on BRSK1
Each point is one of the 92 approved drugs; color = inhibition % on BRSK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…